SCHEMBL10304971

SCHEMBL10304971

Cc1ccc(F)cc1-c1cccnc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 1/20 0.56
▸ NISCH Q9Y2I1 1/20 0.46
▸ PDE2A O00408 4/20 0.46
▸ PDE10A Q9Y233 4/20 0.46
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ CCNA1 P78396 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ CDK5R1 Q15078 1/20 0.41
▸ CCNB3 Q8WWL7 1/20 0.41
▸ ABL1 P00519 3/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10304938 0.87 NISCH (0.49) TDO2NISCHPDE2APDE10AABL1
SCHEMBL15730170 0.85 TDO2 (0.56) TDO2PDE2APDE10ACCNB2CDK1
SCHEMBL10305006 0.84 NPC1 (0.44) TDO2NISCHPDE2APDE10AABL1
SCHEMBL10304948 0.82 NISCH (0.41) TDO2NISCHPDE2APDE10AABL1
SCHEMBL10305040 0.82 NPC1 (0.48) TDO2NISCHABL1
SCHEMBL14886183 0.81 NISCH (0.49) TDO2NISCHPDE2APDE10AABL1
SCHEMBL3421959 0.79 MKNK1 (0.52) TDO2PDE2APDE10AABL1CYP3A4
SCHEMBL31469002 0.79 MKNK1 (0.52) TDO2PDE2APDE10AABL1CYP3A4
SCHEMBL30377758 0.79 NISCH (0.52) TDO2NISCHPDE2APDE10AABL1
SCHEMBL9139591 0.79 NISCH (0.52) TDO2NISCHPDE2APDE10AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 — — US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 — — US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 TDO2 4287/4885NISCH 3415/4885PDE2A 1518/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 TDO2 4287/4885NISCH 3415/4885PDE2A 1518/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 TDO2 4287/4885NISCH 3415/4885PDE2A 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback